GSK报告说,2024年营业额增加了3%,并将销售目标提高到2031年的400多亿英镑。 GSK reports a 3% rise in 2024 turnover and raises sales target to over £40 billion by 2031.

GlaxoSmithKline(GSK)制药公司报告,2024年营业额增长3%,达到314亿英镑,其驱动因素是特种药品销售额增长19%,肿瘤药物增长98%。 Pharmaceutical company GlaxoSmithKline (GSK) reported a 3% rise in 2024 turnover to £31.4 billion, driven by a 19% increase in specialty medicines sales and a 98% jump in oncology drugs. 尽管疫苗销售量下降了4%,由于合法结算,营业利润下降了40%,但全球疫苗公司将其长期销售目标从380亿英镑提高到2031年的400亿英镑。 Despite a 4% drop in vaccine sales and a 40% decrease in operating profits due to legal settlements, GSK raised its long-term sales target to over £40 billion by 2031 from £38 billion. 该公司还计划进行20亿英镑的股票回购和增加红利。 The company also plans a £2 billion share buyback and increased dividends.